Biomarkers in Blood Samples From Patients With HIV Infection and Stage III or Stage IV Hodgkin Lymphoma Undergoing Chemotherapy



Status:Terminated
Conditions:HIV / AIDS, Lymphoma
Therapuetic Areas:Immunology / Infectious Diseases, Oncology
Healthy:No
Age Range:18 - Any
Updated:4/21/2016
Start Date:June 2011
End Date:January 2013

Use our guide to learn which trials are right for you!

Quantification of HIV-1 Reservoirs in HIV-Positive Persons Receiving Response-Adapted Therapy for Stage III-IV Hodgkin Lymphoma: A Companion Protocol to SWOG Protocol S0816 (AMC-073)

RATIONALE: Studying samples of blood in the laboratory from patients undergoing treatment
with HIV infection and Hodgkin lymphoma may help doctors learn more about the effects of
therapy on HIV.

PURPOSE: This research study is studying biomarkers in blood samples from patients with HIV
infection and stage III or stage IV Hodgkin lymphoma undergoing chemotherapy.

OBJECTIVES:

Primary

- To quantify HIV-1 persistence in prospectively collected samples from patients on
suppressive antiretroviral therapy undergoing chemotherapy for Hodgkin lymphoma.

OUTLINE: This is a multicenter study.

Blood samples are collected before, during, and after treatment for lymphoma for HIV-1 RNA
levels using standard and single copy assays and HIV-1 DNA quantification (peripheral blood
mononuclear cells).

After completion of treatment, patients are followed up periodically for up to 2 years.

DISEASE CHARACTERISTICS:

- HIV-1 infection, as documented by a rapid HIV test or any FDA-approved HIV-1 enzyme
or chemiluminescence immunoassay (E/CIA) test kit and confirmed by western blot at
any time prior to study entry

- Documentation may be serologic (positive ELISA and positive western blot), or
other federally approved licensed HIV diagnostic test

- Prior documentation of HIV seropositivity is acceptable

- Diagnosis of untreated Hodgkin lymphoma and participation in the parent protocol
SWOG-S0816, "A Phase II Trial of Response Adapted Therapy of Stage III-IV Hodgkin
Lymphoma Using Early Interim FDG-PET Imaging."

PATIENT CHARACTERISTICS:

- No psychosocial conditions that would prevent study compliance and follow-up, as
determined by the principal investigator

- Willing to provide serial blood samples

PRIOR CONCURRENT THERAPY:

- See Disease Characteristics
We found this trial at
1
site
Baltimore, Maryland 21231
410-955-6190
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins The name Johns Hopkins has become synonymous...
?
mi
from
Baltimore, MD
Click here to add this to my saved trials